CREATIVE MEDICAL TECHNOLOGY HOLDINGS Business Summary

Creative Medical Technology Holdings, Inc. (CELZ) is a clinical-stage biotechnology firm specializing in regenerative medicine and immunotherapy, primarily generating revenue through the creation and licensing of intellectual property and strategic partnerships. The company operates across three core technology platforms: AlloStem (olastrocel), an allogeneic perinatal tissue-derived cell therapy currently in the FDA-cleared ADAPT trial for chronic lower back pain; ImmCelz (etaroleucel), an autologous regulatory T-cell (Treg) immunotherapy targeting Type 1 diabetes; and iPScelz, an AI-integrated induced pluripotent stem cell platform utilized in its BioDefense Burn Pit Initiative. CELZ competes in the crowded regenerative medicine space against small-cap peers such as IO Biotech (IOBT), Pasithea Therapeutics (KTTA), Klotho Neurosciences (KLTO), and Lexaria Bioscience (LEXX). As a micro-cap entity, CELZ differentiates itself through a high-density IP portfolio of over 60 patents and a capital-efficient model that leverages existing strategic partnerships to advance clinical milestones without immediate incremental fundraising. The leadership team is led by Co-Founder, President, and CEO Timothy Warbington, an entrepreneur with over 12 years of healthcare executive experience who transitioned from a background in agricultural finance and early-stage biotech consulting to found the company in 2011. Supporting the executive suite is Donald Dickerson, who serves as Chief Financial Officer and Senior Vice-President, overseeing the company's disciplined financial strategy and recent warrant exercise initiatives. Scientific and clinical execution is managed by Courtney Bartlett, Director of Clinical Development, while the company’s research foundation remains heavily influenced by the work of stem cell pioneer Dr. Thomas Ichim. The company’s board includes Bruce Urdang, Michael Finger, and Susan Snow, with institutional backing from notable investors such as Armistice Capital LLC, Vanguard Group, and Geode Capital Management, which maintain minority positions in the company’s equity structure.